I suspect a DNA vaccine will have lower cost of manufacture than the known competitors -- quality control should also be less an issue. However, Admedus does need to at least match clinical outcomes of competitors.
Depending on any adjuncts required & delivery method, I would hope any products coming out of Admedus are stable at room temperature - not sure about the competitors. Also interesting is whether this vaccine will be a candidate for nano-patch delivery rather than traditional injection. That tech was developed in Qld too -- but now owned by a US company commercialising it.
Phase 2 commencing this year is good news.
Ann: Admedus announces further data from HSV-2 Trial, page-76
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |